Company MORPHOSYS Swiss Exchange

Equities

OXMOR

DE0006632003

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Other Biotechnology & Medical Research

Inactive Instrument

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

EUR in Million	2022	Weight	2023	Weight	Delta
Innovative Cancer Medicines 100.0 %	278	100.0 %	238	100.0 %	-14.37%

EUR in Million	2022	Weight	2023	Weight	Delta
United States 88.8 %	0	0.0 %	211	88.8 %	-
Europe (excluding Germany) 11.2 %	-	-	27	11.2 %	-
Asia 0.0 %	-	-	0	0.0 %	-

Managers	Title	Age	Since
Jean-Paul Kress CEO	Chief Executive Officer	59	01/19/01
Lucinda Crabtree DFI	Director of Finance/CFO	45	07/23/07
Luisa Ciccarelli CTO	Chief Tech/Sci/R&D Officer	-	01/21/01
Tim Demuth CTO	Chief Tech/Sci/R&D Officer	50	01/22/01
Julia Neugebauer IRC	Investor Relations Contact	-	01/06/01
Daniel Palmacci PRN	Corporate Officer/Principal	-	01/20/01
Ann Merchant PRN	Corporate Officer/Principal	59	01/18/01
Ralf Ostendorp PRN	Corporate Officer/Principal	-	01/99/01
Günter Wellnhofer PRN	Corporate Officer/Principal	-	01/94/01
Klaus de Wall AUD	Comptroller/Controller/Auditor	-	01/05/01

Members of the board	Title	Age	Since
Michael Brosnan BRD	Director/Board Member	69	17/18/17
George Golumbeski BRD	Director/Board Member	67	17/18/17
Marc Cluzel CHM	Chairman	69	31/12/31
Andrew Cheng BRD	Director/Board Member	57	18/22/18
Krisja Vermeylen BRD	Director/Board Member	62	01/17/01
Sharon Curran BRD	Director/Board Member	56	22/19/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	37,716,423	31,830,703 ( 84.39 %)	53,685 ( 0.1423 %)	84.39 %

Name	Equities	%	Valuation
NOVARTIS AG 11.56 %	4,360,100	11.56 %	309 M €
Goldman Sachs & Co. LLC (Private Banking) 10.98 %	4,141,089	10.98 %	293 M €
Kynam Capital Management LP 10.61 %	4,000,000	10.61 %	283 M €
Adage Capital Management LP 5.011 %	1,890,000	5.011 %	134 M €
RP Management LLC (Investment Management) 3.546 %	1,337,552	3.546 %	95 M €
Norges Bank Investment Management 2.813 %	1,061,012	2.813 %	75 M €
Caligan Partners LP 2.805 %	1,057,962	2.805 %	75 M €
DWS Investment GmbH 2.301 %	868,004	2.301 %	61 M €
Baillie Gifford & Co. 2.215 %	835,292	2.215 %	59 M €
Credit Suisse Asset Management Ltd. 0.3477 %	131,136	0.3477 %	9 M €

Name	Equities	%	Valuation
T. Rowe Price Investment Management, Inc. 4.263 %	6,431,063	4.263 %	117 M €
Kynam Capital Management LP 2.807 %	4,234,685	2.807 %	77 M €
Point72 Asset Management LP 2.521 %	3,802,846	2.521 %	69 M €
T Rowe Price Associates, Inc. (13F Subfiler) 1.798 %	2,712,552	1.798 %	49 M €
Logos Global Management LP 0.9777 %	1,475,000	0.9777 %	27 M €
Balyasny Asset Management LP 0.8643 %	1,303,945	0.8643 %	24 M €
UBS Financial Services, Inc. 0.7738 %	1,167,338	0.7738 %	21 M €
Aperio Group LLC 0.6747 %	1,017,852	0.6747 %	18 M €
Carlson Capital LP 0.6300 %	950,461	0.6300 %	17 M €
Segantii Capital Management Ltd. 0.3072 %	463,466	0.3072 %	8 M €

MorphoSys AG

Semmelweisstrasse 7

82152, Planegg

+49 89 899 27-0

http://www.morphosys.de

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+29.77%	4.92TCr
IQVIA HOLDINGS INC.	+1.00%	4.21TCr
LONZA GROUP AG	+50.47%	4.04TCr
CELLTRION, INC.	-5.26%	2.89TCr
ICON PUBLIC LIMITED COMPANY	+13.68%	2.61TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	1.87TCr
BIO-TECHNE CORPORATION	+8.22%	1.33TCr
MEDPACE HOLDINGS, INC.	+32.41%	1.23TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	1.2TCr

Other Biotechnology & Medical Research